Literature DB >> 15475990

Outpatient Parenteral Antimicrobial Therapy (OPAT): a review of experience at Auckland Hospital.

Arlo Upton1, Rod B Ellis-Pegler, Andrew Woodhouse.   

Abstract

AIM: To review the Auckland Hospital Outpatient Parenteral Antimicrobial Therapy (OPAT) Service.
METHODS: Patients (>15 years of age) were referred to the Service and assessed for suitability for outpatient therapy by an infectious diseases physician and a specialist nurse. Patient demographics, referring service, site of infection, and infecting organism, antimicrobial agent/s and outcomes of treatment including complications were recorded.
RESULTS: Over a 20-month period 100 patients were treated with 107 courses of outpatient parenteral antibiotic therapy. Bone and joint infections accounted for close to two thirds (60%) of the referrals; discitis/osteomyelitis (36%), septic arthritis (14%) and infected metalware/prosthetic joint infections (10%). Staphylococcus aureus was the most frequently isolated organism (42%), and in 21% of cases no organism was identified. In general, antibiotics prescribed were narrow spectrum and all but six patients self-administered up to four times daily. Eighty-eight percent of treatment courses resulted in a cure. Complications related to therapy occurred in 35% of patients.
CONCLUSIONS: We have found that parenteral antibiotic therapy can be administered safely and successfully in an outpatient setting despite relatively frequent dosing intervals. The majority of complications were minor, and 88% of patients were cured.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475990

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  9 in total

1.  The Impact of an Infectious Diseases Transition Service on the Care of Outpatients on Parenteral Antimicrobial Therapy.

Authors:  Sara C Keller; Danielle Ciuffetelli; Warren Bilker; Anne Norris; Daniel Timko; Alex Rosen; Jennifer S Myers; Janet Hines; Joshua Metlay
Journal:  J Pharm Technol       Date:  2013-10

2.  Self-administration of outpatient parenteral antibiotic therapy and risk of catheter-related adverse events: a retrospective cohort study.

Authors:  D A Barr; L Semple; R A Seaton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-12       Impact factor: 3.267

3.  Self-administered outpatient parenteral antimicrobial therapy: a report of three years experience in the Irish healthcare setting.

Authors:  J Kieran; A O'Reilly; J Parker; S Clarke; C Bergin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-08-21       Impact factor: 3.267

4.  Outpatient parenteral antimicrobial therapy for surgery patients: A comparison with previous standard of care.

Authors:  Anjie Yang; Ron Fung; James Brunton; Linda Dresser
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

5.  Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.

Authors:  C Gardiol; R Voumard; C Cochet; S de Vallière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-17       Impact factor: 3.267

6.  Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy.

Authors:  Sara C Keller; Deborah Williams; Mitra Gavgani; David Hirsch; John Adamovich; Dawn Hohl; Ayse P Gurses; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

Review 7.  Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review.

Authors:  E D Mitchell; C Czoski Murray; D Meads; J Minton; J Wright; M Twiddy
Journal:  BMJ Open       Date:  2017-04-20       Impact factor: 2.692

8.  Benefit of Echocardiography in Patients With Staphylococcus aureus Bacteremia at Low Risk of Endocarditis.

Authors:  George S Heriot; Steven Y C Tong; Allen C Cheng; Danny Liew
Journal:  Open Forum Infect Dis       Date:  2018-12-11       Impact factor: 3.835

9.  Outpatient parenteral antimicrobial therapy with ceftriaxone for acute tonsillopharyngitis: efficacy, patient satisfaction, cost effectiveness, and safety.

Authors:  Samah Al Alawi; Somaya Abdulkarim; Hazem Elhennawy; Anwar Al-Mansoor; Ahmed Al Ansari
Journal:  Infect Drug Resist       Date:  2015-08-07       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.